Current and potential uses of imiquimod

被引:56
作者
Chang, YC
Madkan, V
Cook-Norris, R
Sra, K
Tyring, S
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Dermatol, Houston, TX 77030 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA
[3] Ctr Clin Studies, Houston, TX USA
[4] Texas Tech Univ, Sch Med, Lubbock, TX 79409 USA
[5] Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77550 USA
关键词
imiquimod; immune response modifier; antiviral; antitumor;
D O I
10.1097/01.SMJ.0000176712.01491.98
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Imiquimod, an imidazoquinoline amine, is an immune response modifier first FDA-approved for the treatment of external genital and perianal warts in 1997. Since its appearance on the market, its antiviral and antitumor properties have been used in the treatment of a variety of dermatologic conditions. In this review article, the basic mechanism of action of imiquimod, current FDA-approved and non-FDA-approved uses of imiquimod, and key points of medication application frequency, possible adverse effects, and use in combination therapy are discussed. Common skin conditions that may be eradicated with imiquimod are emphasized.
引用
收藏
页码:914 / 920
页数:7
相关论文
共 42 条
[21]   Infantile hemangioma - Clinical resolution with 5% imiquimod cream [J].
Martinez, MI ;
Sanchez-Carpintero, I ;
North, PE ;
Mihm, MC .
ARCHIVES OF DERMATOLOGY, 2002, 138 (07) :881-884
[22]  
*MICROMEDEX THOMPS, 2002, DRUG INF HLTH CAR PR
[23]   Imiquimod applied topically: a novel immune response modifier and new class of drug [J].
Miller, RL ;
Gerster, JF ;
Owens, ML ;
Slade, HB ;
Tomai, MA .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1999, 21 (01) :1-14
[24]   Treatment of lentigo maligna with topical imiquimod [J].
Naylor, MF ;
Crowson, N ;
Kuwahara, R ;
Teague, K ;
Garcia, C ;
Mackinnis, C ;
Haque, R ;
Odom, C ;
Jankey, C ;
Cornelison, RL .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 :66-69
[25]   Topical imiquimod immunotherapy in the management of lentigo maligna [J].
Powell, AM ;
Russell-Jones, R ;
Barlow, RJ .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2004, 29 (01) :15-21
[26]  
Ross Gayle L, 2004, Australas J Dermatol, V45, P100, DOI 10.1111/j.1440-0960.2004.00066.x
[27]   Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial [J].
Salasche, SJ ;
Levine, N ;
Morrison, L .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (04) :571-577
[28]   Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study [J].
Schacker, TW ;
Conant, M ;
Thoming, C ;
Stanczak, T ;
Wang, Z ;
Smith, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) :3243-3248
[29]   Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma - Comparison of dosing regimens [J].
Shumack, S ;
Robinson, J ;
Kossard, S ;
Golitz, L ;
Greenway, H ;
Schroeter, A ;
Andres, K ;
Amies, M ;
Owens, M .
ARCHIVES OF DERMATOLOGY, 2002, 138 (09) :1165-1171
[30]   Topically applied imiquimod inhibits vascular tumor growth in vivo [J].
Sidbury, R ;
Neuschler, N ;
Neuschler, E ;
Sun, P ;
Wang, XQ ;
Miller, R ;
Tomai, M ;
Puscasiu, E ;
Gugneja, S ;
Paller, AS .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (05) :1205-1209